Abstract

PHARMACOLOGY AND PHARMACOKINETICS OF EZETIMIBE AND SIMVASTATIN FOR DYSLIPIDEMIA

Irma Novrianti*, Faizal Mustamin and Suharjono

Abstract

Cardiovascular disease involves cardiovascular systems: heart, blood vessels, and blood circulation system. One of the main risks of cardiovascular disease is arteriosclerosis resulted from dyslipidemia in which LDL cholesterol increases. Simvastatin is one of the derivatives of Statins also known as 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase used to reduce cholesterol. Ezetimibe reduces cholesterol by working in the brush border located in the small intestine to block the reabsorption of cholesterol. As a result, less cholesterol is taken to the liver. The combination of ezetimibe (10mg) and simvastatin (10, 20, 40 mg) is effective in reducing the level of LDL-C, so it can be used to cure dyslipidemia suffered by patients with an increased cardiovascular disease risk.

Keywords: Ezetimibe, Simvastatin, Dyslipidemia.